A retrospective look at men on an androgen receptor pathway inhibitor (ARPI) for metastatic castrate-resistant prostate cancer demonstrates roughly half of men achieve a ≥50% reduction in PSA with Lu177-PSMA whether continuing ARPI (n=106) or not (150). | Muniz, Eur Urol Oncol 2025
